|	No.	|	Manufacturer / WHO EUL holder 	|	Name of Vaccine 	|	NRA of Record 	|	Platform 	|	EOI accepted 	|	Pre- submission meeting held 	|	Dossier accepted for review	|	Status of assessment	|	Anticipated decision date	|
|	---:	|	:---	|	:---	|	:---	|	:---	|	:---	|	:---	|	:---	|	:---	|	:---	|
|	1	|	Pfizer/Biontech	|	BNT162b2 (COMIRNATY Tozinameran (INN))	|	EMA 	|	Nucleoside modified mNRA 	|	Yes	|	Yes	|	Yes	|	Finalized 	|	31.12.20	|
|	2.1	|	Oxford-AstraZeneca	|	AZD1222 	|	EMA 	|	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2. 	|	Yes	|	Yes	|	Accepted core data, Data for Covax sites expected in April 2021 onwards 	|	Finalized core data, Finalised sites: SK-Catalent 16 April 2021, Wuxi (DS)  30 April 2021, Chemo Spain 04 June 2021, Other sites As submitted.	|	16.Apr.21	|
|	2.2	|	Oxford-AstraZeneca	|	AZD1222 	|	MFDS KOREA 	|	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2. 	|	Yes	|	Yes	|	Yes	|	Finalized 	|	15.Feb.21	|
|	3	|	Serum Institute Of India	|	ChAdOx1_nCoV-19 (Covishield) 	|	DCGI 	|	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2. 	|	Yes	|	Yes	|	Yes	|	Finalized 	|	15.Feb.21	|
|	4	|	Janssen Infectious Disease and Vaccines	|	Ad26.COV2.S 	|	EMA 	|	Recombinant, replication- incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein 	|	Yes	|	Yes	|	Core data Yes, Additional sites: Aspen South Africa - Other sites	|	Finalized: US +NL sites, Ongoing: other sites	|	12.Mar.21	|
|	5	|	Moderna	|	mRNA-1273 	|	EMA 	|	mNRA-based vaccine encapsulated in lipid nanoparticle (LNP) 	|	Yes	|	Yes	|	Yes	|	Finalized 	|	30.Apr.21	|
|	6	|	Sinopharm / BIBP (Beijing Bio-Institute of Biological Products Co-Ltd)	|	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (lnCoV) 	|	NMPA 	|	Inactivated, produced in Vero cells 	|	Yes	|	Yes	|	Yes	|	Finalized 	|	07.May.21	|
|	7	|	Sinovac	|	SARS-CoV-2 Vaccine (Vero Cell), Inactivated 	|	NMPA 	|	Inactivated, produced in Vero cells 	|	Yes	|	Yes	|	Yes	|	Finalized 	|	01.Jun.21	|
|	8	|	The Gamaleya National Center of Epidemiology and Microbiology	|	Sputnik V 	|	Russian NRA 	|	Human Adenovirus Vector- based Covid-19 vaccine 	|	Additional information submitted 	|	Several meetings held. 	|	Rolling submission of clinical and CMC data has started. 	|	Additional data (Non- CLIN, CLIN, CMC) Required. Inspections in April, May and June 2021 	|	Will be set after all data is submitted and inspections completed. 	|
|	9	|	CanSinoBIO	|	Ad5-nCoV	|	NMPA	|	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	|	Yes	|	Yes	|	Rolling data starting June 2021 	|	NA	|	NA	|
|	10	|	Novavax	|	NVX-CoV2373 (Covovax)	|	EMA	|	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M adjuvant.	|	Yes	|	Yes	|	NA	|	NA	|	NA	|
|	11	|	Sinopharm / WIBP (Wuhan Institute of Biological Products Co Ltd)	|	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	|	NMPA	|	Inactivated, produced in Vero cells	|	EOI submiited on 30 April and more on 26 May 2021.	|	Planned for 14 June 2021	|	NA	|	NA	|	NA	|
|	12	|	Urevac	|	Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/CV07050101	|	EMA	|	mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)	|	EOI submitted on 12 April	|	Planned for 15 July 2021, based on company request	|	NA	|	NA	|	NA	|
|	13	|	Bharat Biotech, India	|	COVAXIN	|	DCGI	|	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	|	EOI submitted on 19/04/2021. More information required.	|	planned in June 2021	|	NA	|	NA	|	NA	|
|	14	|	Vector State Research Centre of Viralogy and Biotechnology	|	EpiVacCorona	|	Russian NRA	|	Peptide antigen	|	Letter received not EOI. Reply sent on 15/01/2021	|	NA	|	NA	|	NA	|	NA	|
|	15	|	Zhifei Longcom, China	|	Recombinant Novel Coronavirus Vaccine (CHO Cell)	|	NMPA	|	Recombinant protein subunit	|	Response to 2nd EOI sent 29 Jan 2021. Additional expected.	|	NA	|	NA	|	NA	|	NA	|
